Sector News

Pharmaceutical research firm SynteractHCR explores sale: sources

April 13, 2016
Life sciences

SynteractHCR Inc, a privately held U.S. contract research organization (CRO), is exploring a sale that could value it at close to $1.5 billion, including debt, according to people familiar with the matter.

A deal would underscore how the CRO industry has benefited in recent years from pharmaceutical companies’ drive to cut costs, reduce clinical trial times and expand their research and development presence around the world.

SynteractHCR’s owner, private equity firm Gryphon Investors, is working with investment bank Wells Fargo & Co (WFC.N) to run an auction for the company, the people said this week.

SynteractHCR, based in Carlsbad, California, has annual earnings before interest, taxes, depreciation and amortization of aground $160 million, the people added, asking not to be identified because the sale process is confidential.

Gryphon Investors, based in San Francisco, and Wells Fargo declined to comment. SynteractHCR did not immediately respond to a request for comment.

SynteractHCR provides outsourced support to pharmaceutical companies, from drug development to marketing. It was created in its current form in 2008 when Gryphon Investors acquired majority ownership of the company and merged it with another company, Vince & Associates Clinical Research. It has since grown further through acquisitions.

The sale process comes as a string of other private equity-owned pharmaceutical services companies explore divesting themselves or initial public offerings. These include InVentiv Health Inc, eResearch Technology Inc and PCI Pharma Services.

By Carl O’Donnell

Spource: Reuters

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach